Biogen Inc Income Statement Quarterly
BIIB
|
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
|
INCOME STATEMENT
(Quarterly GAAP In millions $) |
(Dec 31 2020)
IV. Quarter |
(Sep 30 2020)
III. Quarter |
(Jun 30 2020)
II. Quarter |
(Mar 31 2020)
I. Quarter |
(Dec 31 2019)
IV. Quarter |
| Unconsolidated Joint Business |
|
- |
- |
- |
|
| Revenuesfromanti C D20therapeuticprograms |
|
- |
- |
- |
|
| Total Revenue |
2,852.60 |
3,376.10 |
3,681.60 |
3,534.30 |
3,671.30 |
| Cost of Goods and Services Sold |
490.70 |
449.10 |
411.10 |
454.30 |
447.10 |
| Gross
Profit |
2,361.90 |
2,927.00 |
3,270.50 |
3,080.00 |
3,224.20 |
| Selling, Administration, Marketing |
-806.20 |
573.10 |
555.10 |
570.10 |
-664.90 |
| Depriciation & Amortization |
196.30 |
63.30 |
61.50 |
71.50 |
422.20 |
| Research & development |
-1,726.10 |
1,140.90 |
647.60 |
551.30 |
-691.70 |
| Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down |
92.50 |
- |
- |
- |
40.20 |
| Other operatinig exp. /-income |
5,404.50 |
19.30 |
- |
- |
2,893.00 |
| Special Items |
- |
- |
- |
- |
- |
| Collaboration Profit Sharing |
-232.90 |
- |
- |
- |
-241.60 |
| Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings |
62.70 |
-29.00 |
10.00 |
-4.60 |
-2.60 |
| Collaborationprofitlosssharing |
166.60 |
73.00 |
21.80 |
71.80 |
181.80 |
| Amortization and Impairment of Acquired Intangible Assets |
-464.80 |
- |
- |
- |
-489.90 |
| Total operating costs including COS |
3,183.30 |
2,289.70 |
1,707.10 |
1,714.40 |
1,893.60 |
| Operating income/-loss
|
-330.70 |
1,086.40 |
1,974.50 |
1,819.90 |
1,777.70 |
|
Other Deductions / - Income |
| Interest expense |
- |
- |
- |
- |
- |
| Interest income |
- |
- |
- |
- |
- |
| Net interest expense/-income |
- |
- |
- |
- |
- |
| Loss (Income) from Equity Method Investments |
-0.30 |
- |
-15.10 |
14.80 |
-88.80 |
| Income from affiliates |
- |
- |
- |
- |
- |
| Sale of Business |
- |
- |
- |
- |
- |
| Financing Loss/ -Income |
- |
- |
- |
- |
- |
| Other loss/ -income |
-683.20 |
128.60 |
-47.90 |
105.70 |
138.10 |
| Total costs & expenses |
2,499.80 |
2,418.30 |
1,644.10 |
1,834.90 |
1,942.90 |
| Income /-loss before income taxes |
352.80 |
957.80 |
2,037.50 |
1,699.40 |
1,728.40 |
| Income taxes expenses/-benefit |
-13.40 |
240.80 |
446.10 |
292.00 |
276.10 |
| Income after income taxes |
357.50 |
703.90 |
1,606.50 |
1,392.60 |
1,439.70 |
| Net income/-loss
of other equity |
18.10 |
-13.10 |
15.10 |
-14.80 |
-12.60 |
| Income Loss From Equity Method Investments Net Of Tax |
- |
- |
- |
- |
- |
| Income/-loss
from cont. Ops. |
357.50 |
703.90 |
1,606.50 |
1,392.60 |
1,439.70 |
| Accounting change |
- |
- |
- |
- |
- |
| Discontinued operations |
- |
- |
- |
- |
- |
| Extraordinary items |
- |
- |
- |
- |
- |
| Net Income/-loss |
357.50 |
703.90 |
1,606.50 |
1,392.60 |
1,439.70 |
| Noncontrolling interests |
-0.40 |
2.40 |
64.40 |
-6.50 |
- |
| Prefered dividends |
- |
- |
- |
- |
- |
| Other |
- |
- |
- |
- |
- |
| Income/-loss to shareholder |
357.90 |
701.50 |
1,542.10 |
1,399.10 |
1,439.70 |
| EBIT |
352.80 |
957.80 |
2,037.50 |
1,699.40 |
1,728.40 |
| EBITD |
443.20 |
1,091.80 |
2,150.40 |
1,819.30 |
1,841.40 |
| EBITDA |
443.20 |
1,091.80 |
2,150.40 |
1,819.30 |
1,841.40 |
| Per
Share (GAAP Quarterly, in $) |
(Dec 31 2020)
IV. Quarter |
(Sep 30 2020)
III. Quarter |
(Jun 30 2020)
II. Quarter |
(Mar 31 2020)
I. Quarter |
(Dec 31 2019)
IV. Quarter |
| Basic EPS (excl. extra
items) |
2.33 |
4.47 |
9.60 |
8.10 |
8.11 |
| Extraordinary items |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Basic Net EPS |
2.33 |
4.47 |
9.60 |
8.10 |
8.11 |
| Basic shares outstanding (Mill.
of Units) |
153.30 |
156.90 |
160.60 |
172.80 |
177.50 |
| EPS other shares |
- |
- |
- |
- |
- |
| Diluted Net EPS |
2.32 |
4.46 |
9.59 |
8.08 |
8.09 |
| Diluted average shares (Mill.
of Units) |
154.00 |
157.20 |
160.90 |
173.10 |
178.00 |
| Dividend per share |
0.461 |
- |
- |
- |
- |
|
|
